<SEC-DOCUMENT>0001181431-14-034243-index.html : 20141016
<SEC-HEADER>0001181431-14-034243.hdr.sgml : 20141016
<ACCEPTANCE-DATETIME>20141014161249
ACCESSION NUMBER:		0001181431-14-034243
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20141013
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141014
DATE AS OF CHANGE:		20141014

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		141155236

	BUSINESS ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rrd417550.htm
<DESCRIPTION>8-K
<TEXT>
Document 1 - file: rrd417550.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>rrd417550_40895.htm
<DESCRIPTION>PRESS RELEASE, DATED OCTOBER 13, 2014, TITLED "DYNAVAX INITIATES PHASE 1/2 STUDY OF TLR-9 AGONIST IMMUNOTHERAPY IN B-CELL LYMPHOMA."
<TEXT>
Document 2 - file: rrd417550_40895.htm

</DOCUMENT>
</SEC-DOCUMENT>